Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study

BACKGROUND: Mucopolysaccharidosis II (MPS II) is associated with a broad spectrum of chronic and progressive, life-limiting symptoms. Idursulfase is approved for MPS II enzyme replacement therapy (ERT) in over 50 countries. This retrospective study evaluated the MPS II burden, organization of clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Guffon, Nathalie, Heron, Bénédicte, Chabrol, Brigitte, Feillet, François, Montauban, Vincent, Valayannopoulos, Vassili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407793/
https://www.ncbi.nlm.nih.gov/pubmed/25887606
http://dx.doi.org/10.1186/s13023-015-0259-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407793/
https://www.ncbi.nlm.nih.gov/pubmed/25887606
http://dx.doi.org/10.1186/s13023-015-0259-0

Ejemplares similares